Kronos Bio, Inc. financial data

Symbol
KRON on Nasdaq
Industry
Pharmaceutical Preparations
Location
1300 S. El Camino Real, Suite 400, San Mateo, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 18, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 818 % -3.33%
Debt-to-equity 35.5 % +16.1%
Return On Equity -75 % -27.7%
Return On Assets -55.4 % -23%
Operating Margin -943 % +51.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61M shares +1.46%
Common Stock, Shares, Outstanding 60.5M shares +2.56%
Entity Public Float 46.3M USD -4.14%
Common Stock, Value, Issued 60K USD +1.7%
Weighted Average Number of Shares Outstanding, Basic 60.1M shares +4.03%
Weighted Average Number of Shares Outstanding, Diluted 60.1M shares +4.03%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.85M USD +56.6%
Research and Development Expense 48.7M USD -42.4%
General and Administrative Expense 24.6M USD -36.8%
Operating Income (Loss) -92.9M USD +23.9%
Nonoperating Income (Expense) 6.81M USD -27.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -86.1M USD +23.6%
Earnings Per Share, Basic -1.43 USD/shares +26.7%
Earnings Per Share, Diluted -1.43 USD/shares +26.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 84.6M USD +31.5%
Assets, Current 115M USD -35.5%
Property, Plant and Equipment, Net 3.82M USD -62.7%
Operating Lease, Right-of-Use Asset 3.18M USD -83.8%
Other Assets, Noncurrent 112K USD -80.6%
Assets 124M USD -41.7%
Accounts Payable, Current 2.4M USD +172%
Employee-related Liabilities, Current 302K USD -92.2%
Accrued Liabilities, Current 7.62M USD -32.8%
Contract with Customer, Liability, Current 1.86M USD -80.6%
Liabilities, Current 15.3M USD -38.1%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 21.5M USD -15.3%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 36.8M USD -32.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 9K USD -52.6%
Retained Earnings (Accumulated Deficit) -595M USD -16.9%
Stockholders' Equity Attributable to Parent 87.6M USD -44.9%
Liabilities and Equity 124M USD -41.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.9M USD -302%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 5.77M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 60.5M shares +2.56%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.1M USD -47.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 86.6M USD +30.5%
Deferred Tax Assets, Valuation Allowance 141M USD +15%
Deferred Tax Assets, Gross 142M USD +11.9%
Operating Lease, Liability 24.9M USD -11.9%
Depreciation 1.74M USD -20%
Payments to Acquire Property, Plant, and Equipment 7K USD -94.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -86.1M USD +23%
Lessee, Operating Lease, Liability, to be Paid 32.6M USD -13.9%
Property, Plant and Equipment, Gross 12.4M USD -29.2%
Operating Lease, Liability, Current 3.39M USD +17.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.41M USD -8.72%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.93M USD +12.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.73M USD -19.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.87M USD -9.82%
Deferred Tax Assets, Operating Loss Carryforwards 80.7M USD +18.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 5.29M USD +21.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.02M USD +3%
Operating Lease, Payments 5.8M USD +3.57%
Additional Paid in Capital 682M USD +2.19%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.28M USD +4.02%
Deferred Tax Assets, Net of Valuation Allowance 191K USD -94.6%
Share-based Payment Arrangement, Expense 14.1M USD -43.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%